{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:47:41Z","timestamp":1787878061115,"version":"build-2784847793"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ejca.2025.116060","type":"journal-article","created":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T22:25:18Z","timestamp":1760999118000},"page":"116060","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Patient-reported outcomes with paclitaxel and ramucirumab switch maintenance in advanced gastroesophageal cancer: A secondary endpoint of the ARMANI phase 3 trial"],"prefix":"10.1016","volume":"231","author":[{"given":"Eleonora","family":"Cristarella","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margherita","family":"Ambrosini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8906-3785","authenticated-orcid":false,"given":"Massimo","family":"Di Maio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7593-8138","authenticated-orcid":false,"given":"Sara","family":"Lonardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferdinando","family":"De Vita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Di Donato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1715-8440","authenticated-orcid":false,"given":"Elisa","family":"Giommoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6955-7139","authenticated-orcid":false,"given":"Andrea","family":"Spallanzani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Bittoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Chini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4463-469X","authenticated-orcid":false,"given":"Antonia","family":"Strippoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiziana Pia","family":"Latiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oronzo","family":"Brunetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Tamberi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni Gerardo","family":"Cardellino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Spada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0187-5904","authenticated-orcid":false,"given":"Lorenzo","family":"Fornaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Alessandrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8530-8420","authenticated-orcid":false,"given":"Filippo","family":"Pietrantonio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Randon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2025.116060_bib1","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","article-title":"Gastric cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Lordick","year":"2022","journal-title":"Ann Oncol"},{"issue":"17","key":"10.1016\/j.ejca.2025.116060_bib2","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1200\/JCO.23.01601","article-title":"First-Line nivolumab plus chemotherapy for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 3-Year Follow-Up of the phase III CheckMate 649 trial","volume":"42","author":"Janjigian","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.116060_bib3","doi-asserted-by":"crossref","unstructured":"Marupuru S., Arku D., Axon D.R., et al. First-Line Systemic Therapy Outcomes in Western Population with Locally Advanced and Metastatic Gastric Cancer-A Systematic Review. Published online 2023. doi:10.3390\/gastroent14040037.","DOI":"10.20944\/preprints202307.0306.v1"},{"issue":"12","key":"10.1016\/j.ejca.2025.116060_bib4","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1016\/S1470-2045(24)00580-1","volume":"25","author":"Randon","year":"2024","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2025.116060_bib5","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The european organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"issue":"14","key":"10.1016\/j.ejca.2025.116060_bib6","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1016\/j.ejca.2007.07.005","article-title":"Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-OG25, to assess health-related quality of life in patients with cancer of the oesophagus, the oesophago-gastric junction and the stomach","volume":"43","author":"Lagergren","year":"2007","journal-title":"Eur J Cancer"},{"issue":"10","key":"10.1016\/j.ejca.2025.116060_bib7","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","article-title":"Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)","volume":"20","author":"Herdman","year":"2011","journal-title":"Qual Life Res"},{"key":"10.1016\/j.ejca.2025.116060_bib8","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv225","article-title":"Design issues in randomized clinical trials of maintenance therapies","volume":"107","author":"Freidlin","year":"2015","journal-title":"J Natl Cancer Inst"},{"issue":"22","key":"10.1016\/j.ejca.2025.116060_bib9","doi-asserted-by":"crossref","first-page":"3210","DOI":"10.1200\/JCO.2006.08.3956","article-title":"Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 study group","volume":"25","author":"Ajani","year":"2007","journal-title":"J Clin Oncol"},{"issue":"35","key":"10.1016\/j.ejca.2025.116060_bib10","doi-asserted-by":"crossref","first-page":"5388","DOI":"10.1200\/JCO.23.00170","article-title":"Health-Related quality of life with nivolumab plus chemotherapy versus chemotherapy in patients with advanced Gastric\/Gastroesophageal junction cancer or esophageal adenocarcinoma from CheckMate 649","volume":"41","author":"Moehler","year":"2023","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2025.116060_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103663","article-title":"Health-related quality of life in patients with CLDN18.2-positive, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma: results from the SPOTLIGHT and GLOW clinical trials","volume":"9","author":"Lordick","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.ejca.2025.116060_bib12","article-title":"Health-related quality of life with bemarituzumab plus mFOLFOX6 in patients with FGFR2b-overexpressing, advanced gastric or gastroesophageal junction cancer","volume":"6","author":"Wainberg","year":"2024","journal-title":"ESMO Gastrointest Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2025.116060_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103654","article-title":"Association between health-related quality-of-life results, outcomes of efficacy and drug approvals: a meta-research study of randomized phase III trials in oncology","volume":"9","author":"Paratore","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.ejca.2025.116060_bib14","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ejca.2018.11.013","article-title":"Association of quality of life with disease characteristics and treatment outcomes in patients with advanced gastric cancer: exploratory analysis of RAINBOW and REGARD phase III trials","volume":"107","author":"Chau","year":"2019","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.ejca.2025.116060_bib15","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/annonc\/mdv625","article-title":"Quality-of-life and performance status results from the phase III RAINBOWstudy of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma","volume":"27","author":"Al-Batran","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2025.116060_bib16","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ejca.2023.04.027","article-title":"Minimally important differences for interpreting EORTC QLQ-C30 change scores over time: a synthesis across 21 clinical trials involving nine different cancer types","volume":"188","author":"Musoro","year":"2023","journal-title":"Eur J Cancer"},{"issue":"0","key":"10.1016\/j.ejca.2025.116060_bib17","article-title":"First-line pembrolizumab plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction adenocarcinoma: Health-related quality of life from the randomized phase III KEYNOTE-859 trial","volume":"0","author":"Lowery","year":"2025","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.ejca.2025.116060_bib18","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1093\/jnci\/djab177","article-title":"Impact of blinding on Patient-Reported outcome differences between treatment arms in cancer randomized controlled trials","volume":"114","author":"Efficace","year":"2022","journal-title":"JNCI Journal National Cancer Institute"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925009463?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925009463?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T17:03:12Z","timestamp":1769792592000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804925009463"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":18,"alternative-id":["S0959804925009463"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2025.116060","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patient-reported outcomes with paclitaxel and ramucirumab switch maintenance in advanced gastroesophageal cancer: A secondary endpoint of the ARMANI phase 3 trial","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2025.116060","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"116060"}}